Skip to content

Lower Limb Movement

All ONWARD® Medical therapies are investigational and not available for commercial use.

Read The Evidence

The STIMO study demonstrated the ability of this therapy to enable long-paralyzed people to stand and walk again with little or no assistance.

We received FDA Breakthrough Device Designation for ARCIM in 2020 to restore leg motor function in people with spinal cord injury. Then in 2021, for the use of the system to normalize blood pressure and provide trunk stability, in 2022 for bladder control, and in 2023 for reduced spasticity.

Other potential indications we may explore include improved sexual function and bowel control, and Parkinson’s mobility and gait.

ARCIM + BCI (brain-computer interface)

We are advancing brain-computer interface (BCI) technology to enhance our ARCIM platform with more natural movement after paralysis.

In partnership with EPFL and CEA-Clinatec, in 2021 we successfully implanted an investigational BCI in a human to augment our ARCIM Therapy with thought-driven movement of the legs after paralysis. The approach was published in Nature in May 2023.

With a European Innovation Council grant to study restoration of thought-driven arm and hand movement after SCI, an additional human was implanted with ARCIM Therapy + BCI in 2023. Three more people are scheduled to participate in the study in 2024.

Contact Us

Please fill out the form
if you would like to contact
us or receive updates

All ONWARD® Medical devices and therapies referenced here, including but not limited to ARCIM®, ARCEX®, ARCBCI™, and ARC Therapy™, alone or in combination with a brain-computer interface (BCI), are investigational and not available for commercial use.